

Axolotl-Derived NeoMatriX® Showcased in National Wound Care Conference

GAINESVILLE, FL, UNITED STATES, October 21, 2025 /EINPresswire.com/ -- A clinical abstract featuring NeXtGen Biologic's NeoMatriX has been accepted as a poster session at the DFCON Conference (Diabetic Foot Conference) in Anaheim, California (October 23–25) the annual conference of the American Limb Preservation Society (ALPS), highlighting [NeoMatriX®](#)'s clinical success in managing chronic diabetic ulcers.



This poster represents the ninth abstract featuring NeXtGen Biologics' NeoMatriX Wound Matrix

“

We are seeing encouraging results with NeoMatriX in treating challenging chronic wounds. With multiple sizes available, it helps clinicians effectively manage both small and large wounds.”

Tracy Winkley

accepted at national conferences, including the Symposium on Advanced Wound Care (SAWC Spring and Fall), where prior poster abstracts have received top-scoring awards for case series studies and rapid-fire presentations highlighting the growing acceptance of this first of its kind technology.

Beauregard Health Systems recently conducted a retrospective review of a [clinical case series](#) using NeoMatriX®, an [FDA-cleared, axolotl-derived ECM](#) collagen matrix medical device, a species uniquely known for its

regenerative capabilities. Dr. Thibodeaux and Tracy Winkley of Beauregard Health Systems will present the poster and share results from the clinical evaluation of NeoMatriX®.

"We are seeing encouraging results with NeoMatriX in treating chronic diabetic foot ulcers," said Tracy Winkley. "In the clinic, both small and large wounds can be challenging, but having NeoMatriX available in a variety of sizes makes it easier to effectively manage these chronic wounds."

Chronic wounds, including diabetic foot ulcers (DFUs), affect about 1.6 million Americans each year and are a leading cause of lower-limb amputations. Over 160,000 people with diabetes undergo amputations annually, most of which are non-traumatic and linked to complications

from the disease. The cost of managing DFUs and related complications exceeds \$9 billion annually in the U.S., highlighting the need for innovative approaches that support improved patient outcomes.

Jonelle Toothman
NeXtGen Biologics, Inc.
+1 904-599-3264

[email us here](#)

Visit us on social media:

[LinkedIn](#)



This press release can be viewed online at: <https://www.einpresswire.com/article/860132572>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.